62/100B416.68
USD
0.61
(0.15%)
Market Closed
Last updated: · Delayed 15 min
BeiGene cash on hand 2013–2026What is a balance sheet? The balance sheet lists what a company owns (assets), what it owes (liabilities) and what is left for its shareholders (equity) on one date.
BeiGene had 5.78B USD in cash and short-term investments on 30 September 2026, up 43.2% on a year before. At the end of fiscal year 2025 it had 4.55B USD.
Last updated 12 Nov 2026 · Next report 25 Feb 2027
Cash on hand
Growth
| Fiscal year | Period ending | Cash on hand | Growth | Total debt | Net cash |
|---|---|---|---|---|---|
| Latest quarter | 30 Sept 2026 | 5.78B | +43.21% | 1.15B | 4.63B |
| FY2025 | 31 Dec 2025 | 4.55B | +73.08% | 2.00B | 2.55B |
| FY2024 | 31 Dec 2024 | 2.63B | -17.23% | 1.08B | 1.55B |
| FY2023 | 31 Dec 2023 | 3.17B | -30.00% | 930.19M | 2.24B |
| FY2022 | 31 Dec 2022 | 4.53B | -31.47% | 596.68M | 3.94B |
| FY2021 | 31 Dec 2021 | 6.62B | +42.29% | 694.64M | 5.92B |
| FY2020 | 31 Dec 2020 | 4.65B | +373.24% | 561.96M | 4.09B |
| FY2019 | 31 Dec 2019 | 982.74M | -44.83% | 277.34M | 705.40M |
| FY2018 | 31 Dec 2018 | 1.78B | +112.71% | 198.40M | 1.58B |
| FY2017 | 31 Dec 2017 | 837.52M | +127.48% | 164.72M | 672.80M |
| FY2016 | 31 Dec 2016 | 368.17M | +266.39% | 17.28M | 350.89M |
| FY2015 | 31 Dec 2015 | 100.49M | +126.35% | 20.79M | 79.70M |
| FY2014 | 31 Dec 2014 | 44.40M | +1,030.79% | 13.84M | 30.56M |
| FY2013 | 31 Dec 2013 | 3.93M | — | 27.36M | -23.44M |
| Quarter | Period ending | Cash on hand | Growth on a year before | Total debt | Net cash |
|---|---|---|---|---|---|
| Q3 FY2026 | 30 Sept 2026 | 5.78B | +43.21% | 1.15B | 4.63B |
| Q2 FY2026 | 30 Jun 2026 | 5.10B | +84.98% | 1.14B | 3.95B |
| Q1 FY2026 | 31 Mar 2026 | 4.79B | +90.42% | 1.15B | 3.64B |
| Q4 FY2025 | 31 Dec 2025 | 4.55B | +73.08% | 2.00B | 2.55B |
| Q3 FY2025 | 30 Sept 2025 | 4.04B | +49.41% | 1.02B | 3.02B |
| Q2 FY2025 | 30 Jun 2025 | 2.76B | +6.30% | 1.03B | 1.73B |
| Q1 FY2025 | 31 Mar 2025 | 2.52B | -9.91% | 996.83M | 1.52B |
| Q4 FY2024 | 31 Dec 2024 | 2.63B | -17.23% | 1.08B | 1.55B |
| Q3 FY2024 | 30 Sept 2024 | 2.70B | -14.88% | 1.10B | 1.60B |
| Q2 FY2024 | 30 Jun 2024 | 2.59B | -26.26% | 1.09B | 1.50B |
| Q1 FY2024 | 31 Mar 2024 | 2.79B | -27.12% | 1.06B | 1.73B |
| Q4 FY2023 | 31 Dec 2023 | 3.17B | -30.00% | 930.19M | 2.24B |
| Q3 FY2023 | 30 Sept 2023 | 3.17B | -37.38% | 579.77M | 2.59B |
| Q2 FY2023 | 30 Jun 2023 | 3.52B | -38.35% | 677.81M | 2.84B |
| Q1 FY2023 | 31 Mar 2023 | 3.83B | -38.63% | 545.19M | 3.29B |
| Q4 FY2022 | 31 Dec 2022 | 4.53B | -31.47% | 596.68M | 3.94B |
| Q3 FY2022 | 30 Sept 2022 | 5.07B | +29.42% | 710.58M | 4.36B |
| Q2 FY2022 | 30 Jun 2022 | 5.70B | +30.16% | 632.65M | 5.07B |
| Q1 FY2022 | 31 Mar 2022 | 6.24B | +29.77% | 671.88M | 5.57B |
| Q4 FY2021 | 31 Dec 2021 | 6.62B | +42.29% | 694.64M | 5.92B |
| Q3 FY2021 | 30 Sept 2021 | 3.92B | -16.99% | 699.54M | 3.22B |
| Q2 FY2021 | 30 Jun 2021 | 4.38B | +38.99% | 680.38M | 3.70B |
| Q1 FY2021 | 31 Mar 2021 | 4.81B | +42.62% | 638.62M | 4.17B |
| Q4 FY2020 | 31 Dec 2020 | 4.65B | +373.24% | 561.96M | 4.09B |
| Q3 FY2020 | 30 Sept 2020 | 4.72B | +283.04% | 243.73M | 4.48B |
| Q2 FY2020 | 30 Jun 2020 | 3.15B | +105.02% | 361.77M | 2.79B |
| Q1 FY2020 | 31 Mar 2020 | 3.37B | +109.10% | 298.05M | 3.08B |
| Q4 FY2019 | 31 Dec 2019 | 982.74M | -44.83% | 277.34M | 705.40M |
| Q3 FY2019 | 30 Sept 2019 | 1.23B | -39.43% | 285.21M | 946.71M |
| Q2 FY2019 | 30 Jun 2019 | 1.54B | +12.28% | 275.38M | 1.26B |
| Q1 FY2019 | 31 Mar 2019 | 1.61B | +10.22% | 270.59M | 1.34B |
| Q4 FY2018 | 31 Dec 2018 | 1.78B | +112.71% | 198.40M | 1.58B |
| Q3 FY2018 | 30 Sept 2018 | 2.03B | +168.51% | 195.97M | 1.84B |
| Q2 FY2018 | 30 Jun 2018 | 1.37B | +236.16% | 209.75M | 1.16B |
| Q1 FY2018 | 31 Mar 2018 | 1.46B | +347.06% | 173.68M | 1.29B |
| Q4 FY2017 | 31 Dec 2017 | 837.52M | +127.48% | 164.72M | 672.80M |
| Q3 FY2017 | 30 Sept 2017 | 757.44M | +271.99% | 158.35M | 599.09M |
| Q2 FY2017 | 30 Jun 2017 | 407.43M | +79.79% | 152.73M | 254.70M |
| Q1 FY2017 | 31 Mar 2017 | 327.48M | +32.46% | 19.90M | 307.57M |
| Q4 FY2016 | 31 Dec 2016 | 368.17M | +266.39% | 17.28M | 350.89M |
| Q3 FY2016 | 30 Sept 2016 | 203.62M | +67.80% | 18.03M | 185.59M |
| Q2 FY2016 | 30 Jun 2016 | 226.62M | +78.91% | 10.55M | 216.07M |
| Q1 FY2016 | 31 Mar 2016 | 247.23M | +456.88% | 6.21M | 241.01M |
| Q4 FY2015 | 31 Dec 2015 | 100.49M | +126.35% | 20.79M | 79.70M |
| Q3 FY2015 | 30 Sept 2015 | 121.34M | — | 20.63M | 100.72M |
| Q2 FY2015 | 30 Jun 2015 | 126.67M | — | 14.05M | 112.62M |
| Q1 FY2015 | 31 Mar 2015 | 44.40M | — | 0.00 | 44.40M |
| Q4 FY2014 | 31 Dec 2014 | 44.40M | — | 13.84M | 30.56M |
Figures in USD at the end of each period. Net cash is cash and short-term investments less total debt; book value per share is on the diluted share count. The latest column is the most recent quarter.
See also:Revenue,Net income,EPS,Shares outstanding,Operating income,Total debt,Free cash flow,Balance sheet
Common questions about BeiGene's cash
Source: Financial Modeling Prep